Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | TERT | O14746 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.43 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | ALPG | P10696 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7862606 | 0.86 | PDE7A (0.49) | MAPTMEN1KMT2APOLBL3MBTL1 | |
| SCHEMBL16814429 | 0.85 | MEN1 (0.38) | MAPTMEN1KMT2AEPAS1L3MBTL1 | |
| SCHEMBL2539419 | 0.85 | MAPT (0.56) | MAPTMEN1KMT2APOLBL3MBTL1 | |
| SCHEMBL443483 | 0.84 | HSD17B10 (0.52) | MAPTMEN1KMT2APOLBL3MBTL1 | |
| SCHEMBL30072571 | 0.84 | HSD17B10 (0.52) | MAPTMEN1KMT2APOLBL3MBTL1 | |
| SCHEMBL6567485 | 0.84 | PIN1 (0.52) | MAPTMEN1KMT2APOLBL3MBTL1 | |
| SCHEMBL30970189 | 0.82 | MAPT (0.52) | MAPTMEN1KMT2APOLBL3MBTL1 | |
| SCHEMBL11819883 | 0.82 | MAPT (0.52) | MAPTMEN1KMT2AEPAS1TERT | |
| SCHEMBL13548695 | 0.82 | MAPT (0.52) | MAPTMEN1KMT2APOLBL3MBTL1 | |
| SCHEMBL16792556 | 0.82 | MAPT (0.52) | MAPTMEN1KMT2APOLBL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025217513-A1 | ACTIVATION OF PLCG2 AS A THERAPEUTIC STRATEGY FOR THE TREATMENT OF ALZHEIMER'S DISEASE | THE TRUSTEES OF INDIANA UNIVERSITY (US) | 2025-10-16 | — | — | WO | disclosed |
| EP-3080099-B1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | HOFFMANN LA ROCHE (CH) | 2018-04-11 | — | — | EP | disclosed |
| EP-2763990-B1 | PYRROLOPYRAZINE KINASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2017-02-22 | — | — | EP | disclosed |
| EP-2763990-B1 | PYRROLOPYRAZINE KINASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2017-02-22 | — | — | EP | disclosed |
| US-9556150-B2 | Inhibitors of bruton's tyrosine kinase | HOFFMANN-LA ROCHE INC. (US) | 2017-01-31 | — | — | US | disclosed |
| US-9556150-B2 | Inhibitors of bruton's tyrosine kinase | HOFFMANN-LA ROCHE INC. (US) | 2017-01-31 | — | — | US | disclosed |
| US-20160311801-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | CHUGAI PHARMACEUTICAL CO. (JP) | 2016-10-27 | — | — | US | disclosed |
| US-20160311801-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | CHUGAI PHARMACEUTICAL CO. (JP) | 2016-10-27 | — | — | US | disclosed |
| EP-3080099-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | F. Hoffmann-La Roche AG (CH) | 2016-10-19 | — | — | EP | disclosed |
| WO-2015086642-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | F. HOFFMANN-LA ROCHE AG (CH) | 2015-06-18 | — | — | WO | disclosed |
| EP-2763990-A1 | PYRROLOPYRAZINE KINASE INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2014-08-13 | — | — | EP | disclosed |
| US-8658646-B2 | Pyrrolopyrazine kinase inhibitors | HOFFMANN-LAROCHE INC. (US) | 2014-02-25 | — | — | US | disclosed |
| US-8658646-B2 | Pyrrolopyrazine kinase inhibitors | HOFFMANN-LAROCHE INC. (US) | 2014-02-25 | — | — | US | disclosed |
| WO-2013030138-A1 | PYRROLOPYRAZINE KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2013-03-07 | — | — | WO | disclosed |
| WO-2013030138-A1 | PYRROLOPYRAZINE KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2013-03-07 | — | — | WO | disclosed |
| US-20130059834-A1 | PYRROLOPYRAZINE KINASE INHIBITORS | HOFFMANN-LA ROCHE INC. | 2013-03-07 | — | — | US | disclosed |
| US-20130059834-A1 | PYRROLOPYRAZINE KINASE INHIBITORS | HOFFMANN-LA ROCHE INC. | 2013-03-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130059834-A1 | PYRROLOPYRAZINE KINASE INHIBITORS | SYK, ZAP70, JAK1 | MAPT 3736/4885MEN1 3956/4885KMT2A 1627/4885 |
| US-20160311801-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | BTK, SYK, LYN | MAPT 3765/4885MEN1 3945/4885KMT2A 2113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.